Recurrent genetic defects on chromosome 7q in myeloid neoplasms

[1]  S. Vincent Rajkumar,et al.  Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.

[2]  S. Miyano,et al.  Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies , 2013, Leukemia.

[3]  A. Jankowska,et al.  Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies , 2013, Leukemia.

[4]  A. Lane,et al.  Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies , 2013, Blood Cancer Journal.

[5]  M. Kaminski,et al.  A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. , 2012, Blood.

[6]  A. Jankowska,et al.  Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. , 2012, Blood.

[7]  Laura Hulea,et al.  CUX1 transcription factors: from biochemical activities and cell-based assays to mouse models and human diseases. , 2012, Gene.

[8]  S. Ogawa,et al.  Novel CUX1 missense mutation in association with 7q− at leukemic transformation of MPN , 2011, American journal of hematology.

[9]  P. Sonneveld,et al.  Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. , 2011, Blood.

[10]  K. McGlynn,et al.  Racial disparities in incidence and outcome in multiple myeloma: a population-based study. , 2010, Blood.

[11]  A. Jankowska,et al.  Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies , 2010, Leukemia.

[12]  H. Drexler,et al.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.

[13]  R. Kuiper,et al.  Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.

[14]  I. Turesson,et al.  Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Gordon.  Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma , 2009 .

[16]  D. Dingli,et al.  Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.

[17]  H. Brenner,et al.  Recent major improvement in long-term survival of younger patients with multiple myeloma. , 2008, Blood.

[18]  M. Meisler,et al.  Evidence for a direct role of the disease modifier SCNM1 in splicing. , 2007, Human molecular genetics.

[19]  P. Dickman,et al.  Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B. Bedell,et al.  Transgenic mice expressing the p75 CCAAT-displacement protein/Cut homeobox isoform develop a myeloproliferative disease-like myeloid leukemia. , 2006, Cancer research.

[21]  A. Nepveu,et al.  Role of the multifunctional CDP/Cut/Cux homeodomain transcription factor in regulating differentiation, cell growth and development. , 2001, Gene.

[22]  M. Poo,et al.  Plexins Are a Large Family of Receptors for Transmembrane, Secreted, and GPI-Anchored Semaphorins in Vertebrates , 1999, Cell.

[23]  M. Scheffner,et al.  Interaction between ubiquitin–protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation , 1999, Nature Cell Biology.

[24]  Edward T Kipreos,et al.  cul-1 Is Required for Cell Cycle Exit in C. elegans and Identifies a Novel Gene Family , 1996, Cell.